Monitoring of neuromuscular blockade during general anaesthesia
Phase 4
Not yet recruiting
- Conditions
- Incidence of reappearance of the muscle relaxation after reversal with neostigmine
- Registration Number
- 2024-517831-28-00
- Lead Sponsor
- Pirkanmaan hyvinvointialue
- Brief Summary
To find the incidence of reappearance of nondepolarizing neuromuscularblock after reversal with neostigmine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised, recruitment pending
- Sex
- Not specified
- Target Recruitment
- 120
Inclusion Criteria
To find the incidence of reappearance of nondepolarizing neuromuscular block after reversal with neostigmine.
Body Mass Index (BMI) <35k9/ mz
AGE 18-65 years
ASA risk class 1-2
Exclusion Criteria
Disease or previous injury of central nervous system
Disease or medication affecting peripheral nervous system
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To find the incidence of reappearance of nondepolarizing neuromuscular block after reversal with neostigmine To find the incidence of reappearance of nondepolarizing neuromuscular block after reversal with neostigmine
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Tampere University Hospital
🇫🇮Tampere, Finland
Tampere University Hospital🇫🇮Tampere, FinlandMaija-Liisa KalliomäkiSite contact+3583311611maija-liisa.kalliomaki@pirha.fi